AP5
| 中文名稱 | AP5 |
|---|---|
| 中文同義詞 | 化合物 T13550;化合物 AP5 |
| 英文名稱 | AP5 |
| 英文同義詞 | 2H-1-Benzopyran-7-propanoic acid, β-cyclopropyl-2-[2-fluoro-4-(2-methoxy-4-pyridinyl)phenyl]-3,4-dihydro-α-methyl-, (αS,βR,2S)-;AP-5,AP5 |
| CAS號 | 1623194-37-5 |
| 分子式 | C28H28FNO4 |
| 分子量 | 461.53 |
| EINECS號 | |
| 相關類別 | |
| Mol文件 | 1623194-37-5.mol |
| 結(jié)構(gòu)式 | ![]() |
AP5 性質(zhì)
| 沸點 | 596.7±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.262±0.06 g/cm3(Predicted) |
| 儲存條件 | Store at -20°C |
| 溶解度 | 溶于二甲基亞砜 |
| 酸度系數(shù)(pKa) | 4.63±0.11(Predicted) |
EC50: 0.49±0.28 nM (GPR40 Receptor)
AP5 is a potent and selective GPR40 AgoPAM that demonstrates excellent in vivo efficacy. In the GK rat oral glucose tolerance test (oGTT), oral administration of AP5 1 h before an oral dextrose challenge shows that AP5 significantly reduces blood glucose levels compared to the vehicle. AP5 is determined to be more efficacious in this model, demonstrating maximally efficacious glucose lowering at a plasma concentration of 4.9 μM at 10 mg/kg.
